Estimated Annual Spending on Aducanumab in the US Medicare Program

JAMA Health Forum. 2022 Jan 14;3(1):e214495. doi: 10.1001/jamahealthforum.2021.4495. eCollection 2022 Jan.


This cross-sectional study examines upper bound and lower bound annualized Medicare costs for administering aducanumab to beneficiaries with the approved indications of mild cognitive impairment or mild dementia.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Aged
  • Antibodies, Monoclonal, Humanized
  • Cognitive Dysfunction* / drug therapy
  • Cross-Sectional Studies
  • Dementia*
  • Humans
  • Medicare
  • United States


  • Antibodies, Monoclonal, Humanized
  • aducanumab